The most commonly reported AEs associated with the 3 approved PARP inhibitors are fatigue, nausea and vomiting, and haematologic AEs such as anaemia and thrombocytopenia.24–26 Consistent with these class effects, the most common E7449-related AE observed in this study was fatigue. The gene discussed is PARP1; the disease is anemia (phenotype).